Infliximab Modulates Cisplatin-Induced Hepatotoxicity in Rats

Cure M. C., Cure E., Kalkan Y., Kirbas A., Tumkaya L., Yilmaz A., ...More

BALKAN MEDICAL JOURNAL, vol.33, no.5, pp.504-511, 2016 (SCI-Expanded) identifier identifier identifier

  • Publication Type: Article / Article
  • Volume: 33 Issue: 5
  • Publication Date: 2016
  • Doi Number: 10.5152/balkanmedj.2016.150576
  • Journal Indexes: Science Citation Index Expanded (SCI-EXPANDED), Scopus, TR DİZİN (ULAKBİM)
  • Page Numbers: pp.504-511
  • Keywords: Carbamoyl-phosphate synthetase 1, carbonic anhydrase, cisplatin, hepatotoxicity, infliximab, tumor necrosis factor alpha, CARBONIC-ANHYDRASE II, INDUCED LIVER-INJURY, OXIDATIVE STRESS, TOPIRAMATE, CANCER, IX
  • Recep Tayyip Erdoğan University Affiliated: Yes


Background: Cisplatin (Cis) is one of the most commonly used antineoplastic drugs. It is used as chemotherapy for many solid organ malignancies such as brain, neck, male and female urogenital, vesical and pulmonary cancers. Infliximab blocks tumor necrosis factor alpha (TNF-alpha). Several studies have reported that infliximab ameliorates cell damage by reducing cytokine levels.